Document Detail

Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.
MedLine Citation:
PMID:  18298349     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) are critical regulators of bone remodeling and RANKL/RANK signaling could also play an important role in the remodeling process of several tissues, such as myocardium. Therefore, we investigated whether the serum concentrations of OPG and RANKL correlate with the serum levels of metalloproteinase-1 (MMP-1), MMP-9 and tissue inhibitors of MMP-1 (TIMP-1), which are known regulators of myocardial healing in acute myocardial infarction (AMI) patients. METHODS: We analyzed blood samples from 51 consecutively hospitalized men with AMI, 12 men with established ischemic heart failure (New York Heart Association category II, NYHA-II) and 12 healthy men age-matched to the NYHA-II patients. Serum levels of MMP-1, MMP-9, TIMP-1, OPG and RANKL were quantified using commercially available ELISA kits. AMI patients were sampled 4 days and 6 months after MI. RESULTS: Our data revealed increased serum levels of OPG, RANKL, MMP-1 and TIMP-1 levels and significant correlations between increased RANKL levels and MMP-1 and TIMP-1 serum levels 6 months after MI. In addition, the ratio OPG/RANKL was very low 6 months after MI, suggesting that the nuclear factor kappa-B signaling is possibly more active 6 months post-MI than it is on day 4 post-MI. CONCLUSIONS: Our data suggest that OPG, RANKL, MMP-1 and TIMP-1 serum levels can be potential mediators of myocardial healing after MI. However, further large studies are needed to confirm the utility of OPG and RANKL as markers of healing after ST elevation in MI.
Antonios Halapas; Achilleas Zacharoulis; Stamatios Theocharis; Apostolos Karavidas; Dimitrios Korres; Kostantinos Papadopoulos; Harris Katopodis; Anastasia Stavropoulou; Peter Lembessis; Costas Xiromeritis; Apostolos Zacharoulis; Michael Koutsilieris
Related Documents :
2148699 - Lipoprotein (a) and coronary heart disease: a prospective case-control study in a gener...
18310509 - Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardi...
7405899 - Reasonableness of use of the serum isoenzymes creatine kinase and lactate dehydrogenase...
15770879 - Tumour necrosis factor alpha and troponin t as predictors of poor prognosis in patients...
7495679 - Usefulness of myosin in the postmortem diagnosis of myocardial damage.
1267859 - Adrenocortical suppression and myocardial infarction in non-arteriosclerotic (virgin) a...
19615769 - Left atrial volume and index by multi-detector computed tomography: comprehensive analy...
24368739 - Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms,...
3954519 - Five-year follow-up of friedreich's ataxia cardiomyopathy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical chemistry and laboratory medicine : CCLM / FESCC     Volume:  46     ISSN:  1434-6621     ISO Abbreviation:  Clin. Chem. Lab. Med.     Publication Date:  2008  
Date Detail:
Created Date:  2008-07-09     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9806306     Medline TA:  Clin Chem Lab Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  510-6     Citation Subset:  IM    
Department of Experimental Physiology, Medical School, University of Athens, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Blood Chemical Analysis / methods*
Case-Control Studies
Echocardiography / methods
Gene Expression Regulation*
Matrix Metalloproteinase 1 / blood*
Middle Aged
Myocardial Infarction / blood*
Osteoprotegerin / blood*
Receptor Activator of Nuclear Factor-kappa B / blood*
Time Factors
Tissue Inhibitor of Metalloproteinase-1 / blood*
Reg. No./Substance:
0/Osteoprotegerin; 0/Receptor Activator of Nuclear Factor-kappa B; 0/Tissue Inhibitor of Metalloproteinase-1; EC Metalloproteinase 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Apolipoprotein E polymorphisms in Mexican patients with coronary artery disease.
Next Document:  Certification of reference materials for detection of the human prothrombin gene G20210A sequence va...